Benzinga · Sep 11, 2026
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.
EX
NASDAQ · EXEL
Exelixis, Inc.
Healthcare · Biotechnology
$56.90
Up+$0.69 (+1.23%)
Updated Sep 16, 2026, 10:39 AM
SID Score
7.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 11.1B
- P/E ratio
- 16.39
- Dividend yield
- 0.00%
- 52-week range
- $33.76 – $59.72
- Volume
- 1.98M
- Avg. volume
- 2.76M
Price performance
EXEL price history
1M range · 20 trading sessions · Daily adjusted prices
EXEL closed at $56.90 after 20 trading sessions, up 7.12% for the selected period.
- Last close
- $56.90
- Period change
- +7.12%
- Period low
- $53.12
- Period high
- $59.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $55.93 | $56.97 | $54.945 | $56.90 | 1.98M |
| Sep 14, 2026 | $56.44 | $57.07 | $55.91 | $56.21 | 1.74M |
| Sep 11, 2026 | $56.76 | $57.43 | $54.545 | $56.12 | 2.92M |
| Sep 10, 2026 | $58.33 | $58.33 | $57.23 | $57.43 | 1.79M |
| Sep 9, 2026 | $57.60 | $58.36 | $56.95 | $58.33 | 1.77M |
| Sep 8, 2026 | $58.97 | $59.41 | $57.55 | $57.67 | 2.54M |
| Sep 4, 2026 | $58.502 | $59.255 | $58.455 | $59.01 | 1.58M |
| Sep 3, 2026 | $58.75 | $59.72 | $58.195 | $59.13 | 2.14M |
| Sep 2, 2026 | $57.21 | $59.11 | $56.695 | $58.53 | 2.85M |
| Sep 1, 2026 | $54.75 | $56.97 | $54.75 | $56.89 | 2.41M |
| Aug 31, 2026 | $54.10 | $55.02 | $53.4283 | $54.64 | 2.25M |
| Aug 28, 2026 | $55.14 | $55.25 | $54.12 | $54.45 | 1.49M |
| Aug 27, 2026 | $55.76 | $56.08 | $54.83 | $55.26 | 1.49M |
| Aug 26, 2026 | $56.54 | $56.90 | $56.06 | $56.10 | 1.82M |
| Aug 25, 2026 | $54.95 | $56.74 | $54.95 | $56.72 | 2.02M |
| Aug 24, 2026 | $53.89 | $54.79 | $53.39 | $54.55 | 2.42M |
| Aug 21, 2026 | $53.74 | $54.68 | $53.70 | $54.08 | 1.95M |
| Aug 20, 2026 | $53.76 | $54.50 | $53.44 | $53.69 | 1.95M |
| Aug 19, 2026 | $53.46 | $54.58 | $53.10 | $54.39 | 2.5M |
| Aug 18, 2026 | $52.32 | $53.36 | $52.11 | $53.12 | 1.29M |
Latest EXEL news
The latest Smart Investors Daily articles mentioning EXEL.
Stock researchCompany · Overview
EXEL research
Overview
Company profile and research snapshot.
Company profile
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $43.82
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | BMO Capital | Market Perform | — |
| Aug 6, 2026 | Truist Securities | Hold | — |
| Aug 6, 2026 | Stifel | Hold | — |
| Jul 23, 2026 | Morgan Stanley | Equal-Weight | — |
| Jul 14, 2026 | Barclays | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 11, 2026
Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months
Exelixis Inc (NASDAQ:EXEL) shares fell 3. 5% in premarket trading Friday after the company said the US Food and Drug Administration extended the review period for its new drug application for zanzalintinib by three months.
Benzinga · Sep 11, 2026
Exelixis Announces Three-Month FDA Review Period Extension For Its Zanzalintinib New Drug Application In Combination With Atezolizumab For The Treatment Of Metastatic Colorectal Cancer
In response to an FDA information request, Exelixis had submitted updated safety and efficacy data, which the FDA has deemed a major amendment. The updated Prescription Drug User Fee Act action date is March 3, 2027.
SeekingAlpha · Sep 9, 2026
Exelixis, Inc. (EXEL) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Exelixis, Inc. (EXEL) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 8:40 AM EDTCompany ParticipantsAndrew Peters - Senior Vice...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
